HPL vs. FBS for MSC Expansion — Which Performs Better?

Human Platelet Lysate has moved from niche alternative to mainstream supplement for MSC expansion in clinical and GMP settings. The HPL market is growing at 15.19% CAGR through 2035 — driven almost entirely by the shift from FBS in cell therapy manufacturing. Here is what the data actually shows.

Why the Shift Is Happening Now

For decades, FBS was the default supplement for MSC expansion. The shift to HPL is not driven by ideology — it is driven by three converging forces that have reached a tipping point in 2024–2026:

• Regulatory signal: Both EMA and FDA increasingly request justification for xenogenic components in ATMP manufacturing. FBS is not prohibited, but HPL eliminates a regulatory discussion that is becoming harder to win
• Clinical performance: Multiple peer-reviewed studies now demonstrate that HPL-expanded MSCs maintain immunophenotype, differentiation potential and paracrine function at least as well as FBS-expanded cells — often better
• Expansion efficiency: HPL-expanded MSCs typically show higher proliferation rates than FBS-expanded cells, reducing the number of passages required to reach target cell numbers for clinical doses

Head-to-Head Comparison: HPL vs. FBS for MSC Expansion

The HPL Advantage in Proliferation

HPL is exceptionally rich in platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor-beta (TGF-β), insulin-like growth factor (IGF) and epidermal growth factor (EGF). This growth factor cocktail is directly relevant to MSC proliferation — more so than the largely undefined growth factor composition of FBS.

In practical terms: MSCs typically reach passage targets 30–50% faster in HPL-supplemented media compared to FBS. For clinical manufacturing where cell dose requirements are fixed and timelines are tight, this is a significant operational advantage.

The Heparin Question

Standard HPL preparations contain heparin, used during the freeze-thaw lysis process to prevent clotting. For most MSC expansion protocols, heparin at the concentrations present in standard HPL (typically 2–4 IU/ml in the final medium) is not problematic. However, for certain sensitive applications — particularly where heparin might interfere with downstream analytical assays or where heparin-sensitive cells are involved — heparin-free HPL formulations are now available.

Heparin-free HPL is manufactured using alternative lysis protocols and is the preferred choice for any application where heparin interference is a concern. It typically carries a price premium of 15–25% over standard HPL.

Practical Protocol: Transitioning from FBS to HPL

• Starting concentration: 0.75% HPL is approximately equivalent to 10% FBS for MSC proliferation. Start at 5% HPL if you prefer a more direct substitution
• Medium base: DMEM low glucose or alpha-MEM are both compatible with HPL supplementation
• Heparin supplementation: if using heparin-free HPL in a medium without heparin, add 2 IU/ml heparin to prevent gelation during culture
• First passages: expect slightly altered morphology in the first 1–2 passages as cells adapt — this is normal and does not indicate loss of identity
• Lot qualification: run a comparability study against your FBS reference lot before full transition